At least six Chinese companies have filed for New York listings in recent weeks after a clampdown last year by regulators in China, but they are for small IPOs from $1 million to $35 million in size

Healthcare supplies maker Meihua International Medical Technologies is on track to price its debut share sale, which would raise up to $57.5 million

While the pricing has not yet been set, analysts expect the IPO to potentially earn the government close to 75,000 crore rupees (about $10 billion)

Geopolitical worries have added another layer of volatility to an already-jumpy market as investors price in the possibility of escalating conflict between Russia and Ukraine

Local financial media Cailianshe said Zhenro had denied market speculation it had plans to restructure its dollar bonds

The company's direct-to-consumer sales in China rose 35% in the third quarter, compared with an 85.9% jump in the second quarter

The recommendation, which sent Innovent shares down, raises concerns for other Chinese drugmakers seeking to bring products to the US market

Quarz has asked Mapletree North Asia Commercial Trust to negotiate an improved offer from Mapletree Commercial Trust, according to an open letter

The Hang Seng Mainland Properties Index rose 3%, versus a 0.3% loss for the main Hang Seng Index

The Chinese developer, with more than $300 billion in liabilities, has been struggling to repay creditors, suppliers, and deliver homes

US resorts delivered revenue above pre-pandemic levels, but Disney expects international parks to be affected by Covid-19 for weeks to come

The ADS registration might also suggest potential selling intention by SoftBank, Citigroup analysts said this week